Implication of a Rare Deletion at Distal 16p11.2 in Schizophrenia

Saurav Guha, PhD; Elliott Rees, MRs; Ariel Darvasi, PhD; Dobril Ivanov, PhD; Masashi Ikeda, MD, PhD; Sarah E. Bergen, PhD; Patrik K. Magnusson, PhD; Paul Cormican, Phd; Derek Morris, PhD; Michael Gill, MRCPsych, PhD; Sven Cichon, PhD; Jeffrey A. Rosenfeld, PhD; Annette Lee, PhD; Peter K. Gregersen, PhD; John M. Kane, MD; Anil K. Malhotra, MD; Marcella Rietschel, MD; Markus M. Nöthen, MD; Franziska Degenhardt, PhD; Lutz Prieb, MSC; René Breuer, MSC; Jana Strohmaier, Dipl Psych; Douglas M. Rudmer, MSC; Jennifer L. Moran, PhD; Kimberly D. Chambert, MSC; Alan R. Sanders, MD; Jianxin Shi, PhD; Kenneth Kendler, MD; Brien Riley, PhD; Tony O’Neill, MD; Dermot Walsh, MD; Dheeraj Malhotra, PhD; Aiden Corvin, MRCPsych, PhD; Shaun Purcell, PhD; Pamela Sklar, MD, PhD; Nakao Iwata, MD, PhD; Christina M. Hultman, PhD; Patrick F. Sullivan, MD, FRANZCP; Jonathan Sebat, PhD; Shane McCarthy, PhD; Pablo V. Gejman, MD; Douglas F. Levinson, MD; Michael J. Owen, PhD, FRCpsych; Michael C. O’Donovan, PhD, FRCpsych; Todd Lencz, PhD; George Kirov, PhD, MRCPsych; for the Molecular Genetics of Schizophrenia Consortium and the Wellcome Trust Case Control Consortium 2

Context: Large genomic copy number variations have been implicated as strong risk factors for schizophrenia. However, the rarity of these events has created challenges for the identification of further pathogenic loci, and extremely large samples are required to provide convincing replication.

Objective: To detect novel copy number variations that increase the susceptibility to schizophrenia by using 2 ethnically homogeneous discovery cohorts and replication in large samples.

Design: Genetic association study of microarray data.

Setting: Samples of DNA were collected at 9 sites from different countries.

Participants: Two discovery cohorts consisted of 790 cases with schizophrenia and schizoaffective disorder and 1347 controls of Ashkenazi Jewish descent and 662 parent-offspring trios from Bulgaria, of which the offspring had schizophrenia or schizoaffective disorder. Replication data sets consisted of 12 398 cases and 17 945 controls.

Main Outcome Measures: Statistically increased rate of specific copy number variations in cases vs controls.

Results: One novel locus was implicated: a deletion at distal 16p11.2, which does not overlap the proximal 16p11.2 locus previously reported in schizophrenia and autism. Deletions at this locus were found in 13 of 13 850 cases (0.094%) and 3 of 19 954 controls (0.015%) (odds ratio, 6.25 [95% CI, 1.78–21.93]; P = .001, Fisher exact test).

Conclusions: Deletions at distal 16p11.2 have been previously implicated in developmental delay and obesity. The region contains 9 genes, several of which are implicated in neurological diseases, regulation of body weight, and glucose homeostasis. A telomeric extension of the deletion, observed in about half the cases but no controls, points to a possible association between this locus and SZ were obtained in- cluding results from their discovery and replication data, the 2 groups became aware of each other’s work and decided to combine results from their discovery and replication cohorts. Using high-resolution microarrays, one group (from New York and Israel) examined an SZ case-control cohort from the Ashkenazi Jewish (AJ) population, whereas the other group

U C O V E R I N G T H E G E N E T I C factors underlying schizophrenia (SZ) has proven difficult despite heritability estimates of up to 80%. Copy number variations (CNVs) at several loci show consistently replicated evidence for association with SZ. These CNVs are individually very rare, are not fully penetrant, and are found cumulatively in approximately 2% of SZ cases; therefore, large samples were required to establish their association. Given their low baseline frequency, further CNV susceptibility loci likely have yet to be discovered.

In the present study, we report the identification of a CNV locus at distal 16p11.2 that increases the risk for SZ. Findings pointing to a possible association between this locus and SZ were obtained independently by 2 teams of investigators. During the process of obtaining replication data, the 2 groups became aware of each other’s work and decided to combine results from their discovery and replication cohorts. Using high-resolution microarrays, one group (from New York and Israel) examined an SZ case-control cohort from the Ashkenazi Jewish (AJ) population, whereas the other group
Methods

BG Trios Sample

Sample Description

The final sample (after quality control [QC]) consisted of 662 BG offspring with all their parents in 638 families (615 families with 1 offspring, 22 families with 2, and 1 family with 3). Details on this cohort have been previously described, but that parents of each trio but not transmitted to the affected offspring constituted the pseudocontrol population listed in the Table under the control headings.

Genotyping and QC

All samples were genotyped on a single-nucleotide polymorphism array (Affymetrix 6.0; Broad Institute). Analysis was performed using software from the manufacturer (Affymetrix Genotyping Console 4.0 software; Broad Institute) one batch at a time, with each batch containing 70 to 90 arrays. The QC process included removal of CNVs if they were from the X or Y chromosome, were less than 15 kilobases (kb), were covered by fewer than 15 probes, or had a probe density (size/probe number) greater than 7500 base pairs. We used the PLINK tool, version 1.07, to exclude CNVs if 30% or more of their length was covered by a segmental duplication (SD). Copy number variation loci with a frequency of greater than 1% were excluded. Individuals with multiple large duplicate CNVs on the same chromosome were excluded because these duplications are likely to be artifacts. Details on all samples are presented in eMaterial 1. For significance for the rate of deletions in the replication sample by 1-tailed Fisher exact test, P = .018; by Cochran Mantel-Haenszel test, P = .04. For significance for the total sample (discovery + replication) by 2-tailed Fisher exact test, P = .0014; by Cochran Mantel-Haenszel test, P = .0031. Odds ratio for replication samples were 4.35 (95% CI, 1.18-16.06); for the total sample, 6.25 (95% CI, 1.78-21.93). The rate of duplications in the region is not significantly different between cases and controls.

Abbreviations: AA, African Americans; EA, European Americans; CNVs, copy number variations; ISC, International Schizophrenia Consortium; GAIN/MGS, Genetic Association Information Network/Molecular Genetics of Schizophrenia Consortium; WTCCC2, Wellcome Trust Case Control Consortium 2.

Details on all samples are presented in eMaterial 1. For significance for the rate of deletions in the replication sample by 1-tailed Fisher exact test, P = .018; by Cochran Mantel-Haenszel test, P = .04. For significance for the total sample (discovery + replication) by 2-tailed Fisher exact test, P = .0014; by Cochran Mantel-Haenszel test, P = .0031. Odds ratio for replication samples were 4.35 (95% CI, 1.18-16.06); for the total sample, 6.25 (95% CI, 1.78-21.93). The rate of duplications in the region is not significantly different between cases and controls.

Available from Illumina, Inc.

Available from the Broad Institute.

Available from NimbleGen.
AJ SAMPLE

Sample Description

Case (n = 1156) and control (n = 2279) samples were selected from an AJ repository (Hebrew University Genetic Resource; http://hugr.huji.ac.il). Patients for the discovery analysis were recruited from hospitalized inpatients at 7 medical centers in Israel. All diagnoses were assigned after direct interview using the Structured Clinical Interview,11 a questionnaire with inclusion and exclusion criteria, and cross-references to medical records. Chronic medical disorders and conditions were recorded on the basis of patient report and hospital records. The inclusion criteria specified that subjects had to be diagnosed as having SZ or schizoaffective disorder by DSM-IV criteria,3 that all 4 grandparents of each subject were reported to be of AJ ethnic origin, and that each subject or the subject’s legal representative had signed the informed consent form. Exclusion criteria included any psychotic disorder due to a general medical condition, substance-induced psychotic disorder, pervasive developmental disorders, or any cluster A (ie, schizotypal, schizoid, or paranoid) personality disorder. Samples from healthy AJ individuals were collected from volunteers at the Israeli Blood Bank; these subjects did not undergo psychiatric screening but reported no chronic disease and were taking no medication at the time of the blood draw. Corresponding institutional review boards and the National Genetic Committee of the Israeli Ministry of Health approved the studies. All samples were fully anonymized immediately after collection, and genomic DNA was extracted subsequently from blood samples through the use of a commercially available kit (Nucleon; Pharmacia). Genotyping and analyses were performed under protocols approved by the institutional review board of the North Shore–Long Island Jewish Health System.

Genotyping and QC

Genotyping was performed with commercially available arrays (HumanOmni1-Quad; Illumina, Inc) according to the manufacturer’s specifications for approximately 1.4 million genome-wide markers (approximately 900 000 single-nucleotide polymorphisms [SNPs] and 500 000 CNV intensity probes). The SNPs were filtered on the following basis: call rate of less than 98%, minor allele frequency of less than 0.02, and Hardy-Weinberg exact test results of P < .000001 in controls. Samples were filtered on the basis of genotype QC filtration criteria: at least 20 probes, at least 100 kb in size, and less than 0.04. Individuals containing more than 500 CNVs (before filtration described in the following paragraphs) were also excluded from the analysis. The final data set contains 790 cases and 1347 controls.

We further excluded CNV calls on the basis of the QC thresholds recommended by each of the respective algorithms. Thus, CNV calls were excluded from further analysis if the log Bayes factor was no greater than 10 in QuantiSNP, if the confidence threshold was no greater than 35 in cnvPartition, or if default QC parameters in PennCNV were not obtained.

After the QC steps, all the CNV calls were merged using the CNVision program.15 The final rare CNV calls were based on consensus calls from all 3 algorithms (with no more than 25% of the length drawn from 1 algorithm only), with the following filtration criteria: at least 20 probes, at least 100 kb in size, and less than 1% frequency in the total sample. Copy number variations of the same type (ie, deletion or duplication) that were separated by at least 3 probes were merged into 1 contiguous segment as recommended by Vacic et al.7 All CNVs were annotated using the CNVision program. Based on previous findings in SZ and other neuropsychiatric disorders,16 purely intergenic CNVs were excluded.

REPLICATION SAMPLES

Evidence for replication of the findings was obtained from 8 case-control samples recruited and genotyped by other teams from the United States, Europe, and Japan. These samples consisted of 12 398 cases and 17 945 controls who underwent genotyping with high-resolution arrays. Details on the samples, genotyping platforms, and QC used by these teams are specified in eMaterial 1. The minimally affected region was covered well by all arrays used by the other teams (eFigure 3).

All coordinates in this study are based on the Human Genome Build NCBI36/hg18.

RESULTS

After stringent QC procedures, 790 cases and 1347 controls from the AJ cohort and 662 probands from 638 BG families were examined for rare large CNVs. Replication was sought in other case-control data sets for any CNVs that were observed in at least 2 cases and no controls (for the AJ cohort) and transmitted at least twice with no non-transmissions in the BG trios cohort. Several relevant CNVs were found in the 2 discovery data sets at loci already reported to increase the risk for development of SZ; because they are already known susceptibility factors, however, we only list them in eTable 4. In the AJ cohort, CNVs...
at 2 additional loci were observed in 2 cases and no controls. These loci were at chromosome 6q14.3 (hg18 coordinates: 85.25-85.58 megabases [Mb]) and 7q33 (133.39-133.50 Mb), but replication evidence was not observed. No other CNV of this type was supported by replication evidence in the BG data (apart from the 16p11.2 deletion). The lists of all rare and large (>100 kb) CNVs in the 2 samples that intersected genes are available as files on request from the authors (AJ SZ CNVs 100 kb.xls and BG SZ trio CNVs 100 kb.xls).

The only CNV of interest that overlapped between the 2 discovery samples was a deletion at the distal region of 16p11.2, with a minimal common region extending from 28.73 to 28.95 Mb (build 36, hg18). This region intersects 9 genes and is flanked by 2 blocks of segmental duplications (SDs). The region does not overlap the known 16p11.2 locus at 29.56 to 30.11 Mb that has been implicated in SZ.10,16,17

Figure. Microdeletions at the distal 16p11.2 region in the present study. The region intersects 9 genes and is flanked by 2 blocks of segmental duplications (SDs). Red lines represent deletions in schizophrenia cases and blue lines represent deletions in control subjects. The double-headed arrows indicate the intervals implicated in the present study (distal 16p11.2 deletion; minimal common region, 28.73-28.95 megabases [Mb], hg18) and the known 16p11.2 copy number variation locus (known proximal 16p11.2 region; minimal common region, 29.56-30.11 Mb). Bp indicates base pair; chr, chromosome; EA, European American; FISH, fluorescent in situ hybridization; GAIN/MGS, Genetic Association Information Network/Molecular Genetics of Schizophrenia Consortium; hg, human genome; RefSeq, Reference Sequence collection; and WTCCC2, Wellcome Trust Case Control Consortium 2.

AJ cohort and 2 offspring from the BG samples, both transmitted from mothers (parents transmitted this CNV in every trio). Duplications at this locus were observed in 1 AJ control and in 1 BG parent (who transmitted it to an affected offspring).

We sought evidence for association between this deletion with SZ in 8 independent case-control cohorts (12,398 cases and 17,945 controls) for which we had access to the raw data (Table and eMaterial 1). Deletions overlapping this region were observed in an additional 9 cases and 3 controls (P = .018, 1-tailed Fisher exact test for the replication sample; odds ratio, 4.35 [95% CI, 1.18-16.06]). Combining the discovery and replication cohorts, we found 13 deletions among 13,850 cases (0.094%) and 3 among 19,954 controls (0.015%) (P = .0014, 2-tailed Fisher exact test; odds ratio, 6.25 [95% CI, 1.78-21.93]). The positions of the CNVs are shown in the Figure. No excess of duplications in cases was found at 16p11.2.
The minimal common region for all deletions reported in the Table encompasses 9 genes within a 220-kb interval flanked by blocks of SD (Figure). Some CNVs extend over the SDs (however, we noted that no CNV in the 16p11.2 region was excluded on the basis of >50% overlap with an SD). Different break points that extend over the flanking SD regions (but do not reach the telomeric region that is free of SDs) are more likely to reflect the different coverage of arrays (eMaterial 2 and eFigure 3) and/or the problems of calling CNVs over repetitive regions rather than different pathogenicity, especially because these regions have fewer genes. Seven deletions cover an additional region of unique DNA sequence at the telomeric side (Figure, the interval free of SDs) that contains further genes. Evidence of pathogenicity of the 7 CNVs that extended over the telomeric region was nearly as strong as for the implicated critical region (7 of 13,850 cases vs 0 of 19,954 controls, \( P = .0019 \), 2-tailed Fisher exact test). However, the critical distal 16p11.2 region remains the more likely candidate owing to its confirmed involvement in other neurodevelopmental disorders discussed in the “Comment” section and the lack of isolated CNVs in the smaller telomeric region. Of the 3 controls with deletions, 1 (in the Swedish data set) was recruited at the age of 45 years and had type 2 diabetes mellitus and high blood pressure but no other medical or psychiatric problems. No further information is available on the 2 anonymized controls from the Wellcome Trust Case Control Consortium 2/Irish data set; one is from the British Blood Transfusion service (therefore presumably healthy), and the other is from the 1958 cohort.

The new distal locus is approximately 600 kb telomeric from the previously implicated proximal 16p11.2 CNV (29.56–30.11 Mb). The CNVs at proximal 16p11.2 have been shown to increase risk for SZ, autism, and developmental delay when duplicated and for autism and developmental delay when deleted. None of the CNVs in our study extend over the proximal region (Figure). We have previously demonstrated that the known SZ-associated CNVs have high mutation rates and that strong selection pressure operates against them. We can estimate the de novo rate for this deletion at 25% based on the present study (2 transmitted deletions and no information on inheritance in the other subjects) and available data sets with a total of 5 de novo occurrences of 20 events with a known inheritance (eTable 3 and eTable 3). This rate approximates to a selection pressure of 0.25. In line with this, we observe the 2 BG proband deletions to be found on different haplotypes and therefore very likely to be independent mutations.

Phenotypic data, where available, indicate a spectrum of typical presentations of SZ with no evidence of intellectual disability or a specific clinical profile (eTable 2). This indication is similar to the lack of specific clinical presentations reported for the other large CNVs implicated in neurodevelopmental disorders. The possible exception is the presence of 2 individuals with obesity and 2 with type 2 diabetes mellitus (plus 1 control with type 2 diabetes mellitus) in line with previous reports. In addition to the 13 cases listed in the Table and eTable 2, the brother of 1 case (in the Japanese sample) carries the same deletion and also has SZ. Further probands had positive family histories of SZ, but we do not know whether their affected relatives also carry the deletion. Although the transmission status of the CNVs is only available for the BG cohort, we further note that both deletions were transmitted maternally.

COMMENT

Several lines of evidence from the literature support the distal 16p11.2 deletion as a true SZ-associated CNV locus. The deletion has been implicated in developmental delay and other clinical phenotypes (details are given in eTable 1), similar to other SZ-associated CNVs.

Briefly, Cooper et al reported a very similar increased rate of 0.1% (15 of 15,767) for this deletion in children with intellectual disability, autism spectrum disorders, and congenital malformations who were referred for genetic testing compared with a control rate of 0.01% (1 of 8329). Similar rates were found in another large study on patients with developmental delay and a range of other abnormal phenotypes: 31 of 23,084 cases (0.13%) and 1 of 7700 controls (0.01%). Of the 6 cases in that study for whom detailed clinical information was available, one had autism, behavioral problems, attention-deficit/hyperactivity disorder, and SZ; another had behavioral problems, attention-deficit/hyperactivity disorder, and bipolar disorder; and a third had autism. Four of these 6 cases were overweight and all 6 had developmental delay. Moreover, additional telomeric extension of the deletion (to approximately 28.4 Mb) was present in 9 of the 31 cases and was never observed in the controls. Similarly, in our study, 7 of the 13 cases demonstrated this telomorphic extension, which was not seen in the controls. The controls used in these studies partially overlap ours, so these control rates are not independent (eTable 1). Additional published reports of distal 16p11.2 deletions include 5 patients from 2 separate families, all of whom have developmental delay and behavioral problems, and 1 child of 4284 patients with mental retardation.

Distal 16p11.2 deletions have also been shown to be enriched in patients with severe early-onset obesity (3 of 300 [1%]) compared with unscreened population controls (2 of 7366 [0.03%]), consistent with the findings in the study by Bachmann-Gagescu et al. The most likely obesity candidate within the distal 16p11.2 region was postulated to be SH2B1 because this gene plays a role in the regulation of body weight and glucose homeostasis in mice. Two of our cases were obese or overweight, and 2 cases and 1 control had type 2 diabetes mellitus (consistent with being overweight, although this information is not available). However, 1 carrier (from Japan) had documented evidence of normal weight, and several did not have recorded evidence of obesity despite being drawn from cohorts that were assessed for this and other medically relevant phenotypes.

Considerable heterogeneity of phenotypic expression has been reported for most large rare CNVs implicated in SZ, with carriers often manifesting nonsyndromic phenotypes, including intellectual disability, autism, epilepsy, obesity, and cardiac disorders.
otropy appears to also be the case for distal 16p11.2 deletions, possibly owing to the presence of multiple genes within the deleted region.

Clinical presentations for distal 16p11.2 deletion carriers are unremarkable for SZ, with diagnoses ranging across all major subtypes: paranoid, catatonic, undifferentiated, and schizoaffective. The age at SZ onset for deletion carriers ranges from 15 to 30 (mean age, 23.4) years, with no clear evidence of early onset. Two parents who transmitted the deletions to probands did not have psychotic disorders, although one had a mood disorder. Of the 3 controls who carry the deletion, one (from Sweden) did not report psychiatric problems at age 45 years, which is past the usual accepted age for the period of risk for SZ. Of the other 2 controls, one had also passed through the risk period (from the 1958 cohort, examined at age 44–45 years [eMaterial 1]) and the third one, a blood donor, is presumably healthy and not receiving any medication. These observations indicate that this CNV does not have full penetrance, similar to most other CNVs implicated in SZ. None of the carriers had any other SZ-associated CNVs.

Mutations in several of the 9 genes within the critical region of distal 16p11.2 have been implicated in neurodevelopmental diseases. Homozygous mutations in the gene TUFM have been described in infants with fatal encephalopathy,\(^{23}\), \(\text{ATP2A1}\) is implicated in Brody disease, in which patients are unable to relax their muscles during exercise,\(^{23}\) and its homologue, \(\text{ATP2A2}\), has been implicated in neuropsychiatric phenotypes.\(^{27}\) In addition, \(\text{ATXN2L}\) (although unknown in function) encodes a protein belonging to the spinocerebellar ataxia family. The remaining genes are involved in immunity or in insulin and leptin signaling (\(\text{SH2B1}\)) or are of unknown function. In addition to the 9 genes in the minimal critical region, the larger CNVs with telomeric extensions include 8 additional deleted genes (7 of them in a DNA region that is free of SDs [Figure]), possibly increasing the pathogenicity of these larger CNVs. Most notable among these 8 genes is \(\text{CLN3}\), for which recessive mutations are associated with Battde disease, characterized by childhood-onset neurodegeneration.\(^{28}\) Moreover, \(\text{CLN3}\) is the only gene in the minimal or the extended region that is implicated in synaptic function on the basis of Gene Ontology annotation. Our previous study of de novo CNVs indicated an enrichment of such genes in SZ-related events; however, \(\text{CLN3}\) is not among the postsynaptic density genes implicated in that study.\(^{4}\) Additional evidence from animal knockout models may help disentangle the contributions of each of these genes to the observed range of phenotypes.

In conclusion, we have obtained strong evidence of the role of a new CNV locus in SZ. Similar to other such loci, it is very rare and increases the risk for other neurodevelopmental phenotypes.

Submitted for Publication: May 31, 2012; accepted July 19, 2012.

Published Online: January 16, 2013. doi:10.1001/2013.jamapsychiatry.71

Author Affiliations: Division of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, New York (Drs Guha, Kane, A. K. Malhotra, and Lencz); Medical Research Council Centre for Neuropsychiatric Genetics and Genomics and Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, Wales (Mr Rees and Drs Ivanov, Owen, O’Donovan, and Kirov); Department of Genetics, The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel (Dr Darvasi); Fujita Health University School of Medicine, Toyoake, Japan (Drs Ikeda and Iwata); Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School (Drs Bergen and Purcell), and Center for Human Genetics Research, Massachusetts General Hospital (Drs Bergen and Purcell), Boston, Massachusetts; Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts (Drs Bergen, Moran, and Purcell and Ms Chamber); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Drs Magnusson and Hultman); Department of Psychiatry, Trinity College Dublin (Drs Cormican, Morris, Gill, and Corvin), and Health Research Board (Dr Walsh), Dublin, Ireland; Institute of Human Genetics (Drs Cichon, Nöthen, and Degenhardt and Mr Priebe) and Department of Genomics, Life and Brain Center (Drs Cichon and Degenhardt and Mr Priebe), University of Bonn, and German Center for Neurodegenerative Diseases (Dr Nöthen), Bonn, Germany; Institute of Neuroscience and Medicine, Research Center Juelich, Juelich, Germany (Dr Cichon); IST/High Performance and Research Computing, University of Medicine and Dentistry of New Jersey, Newark (Dr Rosenfeld); Robert S. Boas Center for Human Genetics and Genomics (Drs Lee and Gregersen) and Center for Psychiatric Neuroscience (Drs Kane, A. K. Malhotra, and Lencz), The Feinstein Institute for Medical Research, Manhasset, New York; Department of Psychiatry, Hofstra University School of Medicine, Long Island, New York (Drs Kane, A. K. Malhotra, and Lencz); Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany (Dr Rietschel, Mr Breuer, and Ms Strohmaier); Division of Psychiatric Genomics, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York (Mr Ruderfer and Drs Purcell and Sklar); Department of Psychiatry and Behavioral Sciences, NorthShore University HealthSystem Research Institute, Evanston, Illinois (Drs Sanders and Gejman); Department of Psychiatry and Behavioral Sciences, University of Chicago, Chicago, Illinois (Drs Sanders and Gejman); National Cancer Institute, Bethesda, Maryland (Dr Shi); Virginia Institute for Psychiatry and Behavioral Genetics (Dr Kendler) and Department of Psychiatry (Dr Riley), School of Medicine, Virginia Commonwealth University, Richmond, and Department of Psychiatry, Queens University, Belfast, Ireland (Dr O’Neill); Beyster Center for Genomics of Psychiatric Diseases, University of California, San Diego, La Jolla (Drs D. Malhotra and Sebat); Departments of Genetics, Psychiatry, and Epidemiology, University of North Carolina at Chapel Hill (Dr Sullivan); Stanley Institute for Cognitive Genomics, Woodbury Genome Center, Cold Spring Harbor Laboratory, Cold Spring Harbor, Cold Spring, New York (Mr McCarthy); and Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California (Dr Levinson).

Correspondence: Todd Lencz, PhD, Division of Psychiatry Research, The Zucker Hillside Hospital, 75-59 263rd
St, Glen Oaks, NY 11004 (tlencz@NSHS.edu); George Kirov, PhD, MRCPsych, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics and Neuroscience and Mental Health Research Institute, Cardiff University, Heath Park, Cardiff CF4 4XN, Wales (Kirov @cardiff.ac.uk).

Author Contributions: Dr Guha and Mr Rees contributed equally to the research. Drs Lencz and Kirov contributed equally to the research. Drs Guha, Lencz, and Kirov and Mr Rees take full responsibility for the integrity of the data.

Conflict of Interest Disclosures: None reported.

Funding/Support: Work at Cardiff University was supported by grant G0800509 from the Medical Research Council Programme and Centre Grants, grant 2 P50 MH066392-05A1 from the National Institute of Mental Health (NIMH), and grant EU-GEI from the European Union. Genotyping was funded by multiple grants to the Stanley Center for Psychiatric Research at the Broad Institute from the Stanley Medical Research Institute, the Merck Genome Research Foundation, and the Herman Foundation. The Zucker Hillside Hospital work was supported by the North Shore–Long Island Jewish Health System Foundation and grants RC2 MH809964 (Dr Lencz), R01 MH084098 (Dr Lencz), P50 MH080173 (Dr A. K. Malhotra), and P30 MH090590 (Dr Kane) from the National Institutes of Health. Molecular Genetics of Schizophrenia Consortium data collection was supported by R01 grants MH67257, MH59588, MH59571, MH59565, MH59587, MH60870, MH59566, MH16175, MH60879, and MH18100 and U01 grants MH46276, MH46289, MH46318, MH79469, and MH79470 from the NIMH. We acknowledge support through Young Investigator Awards (Dr Sanders and Juba Duan, PhD) from the National Alliance for Research on Schizophrenia and Depression and from the Genetic Association Information Network, the Paul Michael Donovan Charitable Foundation, and the Walter E. Nichols, MD, and Eleanor Nichols endowments (Stanford University). Genotyping performed by the Center for Genotyping and Analysis at the Broad Institute of Harvard and Massachusetts Institute of Technology was supported by grant U54 RR020278 from the National Center for Research Resources. The German study was supported by grants 01GS08144 and 01GS08147 from the German Federal Ministry of Education and Research (BMBF), within the context of the Integrated Genome Research Network MooDS (Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia). Genotypic data were provided by the community-based studies of PopGen (Population-based Recruitment of Patients and Controls for the Analysis of Complex Genotype-Phenotype Relationships), Cooperative Health Research in the Region Augsburg, the Heinz Nixdorf Recall study, and MooDS. Genotyping of Wellcome Trust Case Control Consortium 2 samples was funded by grants 085475/B/08/Z and 085475/Z/08/Z from the Wellcome Trust. The British 1958 Birth Cohort DNA collection was funded by grant G0000934 from the UK Medical Research Council and grant 068545/Z/02 from the Wellcome Trust, and the UK National Blood Service controls by the Wellcome Trust. The Japanese cohort was supported in part by research grants from the Ministry of Education, Culture, Sports, Science and Technology; the Ministry of Health, Labor and Welfare; the Core Research for Evolutional Science and Technology; and the Health Sciences Foundation (Research on Health Sciences focusing on Drug Innovation).

Role of the Sponsors: The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.


REFERENCES

8. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-575.


